IXICO PLC (IXI) — Full Year Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the IXICO PLC final results investor presentation. Throughout the quarter presentation, investors will be in listen only mode. Questions are encouraged, they can be submitted at any time by the q and a tab situated in the right corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives in the meeting itself. However, the company can review all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to CEO, Brian Gordon. Good afternoon to you, sir. Thank you very much, and welcome, everyone. Thanks for taking the time to come to this webinar and and listen to our 2024 results. I should probably quickly introduce myself first. I'm a new face, I think, to quite few a few of of you you who've been following IXICO. My name is Brian Gordon. I joined IXICO over the summer, so a few months ago. If you look at my background, which for which we have a slide that I will briefly go over, I started my career in pharma at the likes of Eli Lilly and UCB, names which you may hear us mention in the future as well because they're very much active in this neurology space that we are active at as IXICO, and so those are our customers. And I then moved to more the precision medicine area where I managed platforms not unlike the one which we are managing at IXICO to help inform biomarker research for pharma companies and and help those platforms also go public, which I did with a Swiss startup called Sofia Genetics at the Nasdaq and Foundation Medicine, which was acquired by Roche. I've been hired two weeks ago in order to obviously help the company scale fur...